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Abstract
Background: Progressive airway inflammation and susceptibility to the airway colonisation and infection are
characteristic for the pathophysiology of chronic obstructive pulmonary disease (COPD). Antimicrobial peptides
(AMPs) are central to the function of the innate host immune response against microbial pathogens and are
regulators of inflammation and immunity. S100A7/psoriasin, a recently described AMP, is an essential component
of the human epithelia against invading pathogens and acts as an effector molecule of the host innate defence in
the skin. We hypothesized that S100A7/psoriasin is involved in the airway mucosal immunity and differently
regulated and expressed in the lung during progression of COPD.
Methods: S100A7/psoriasin gene expression was assessed in bronchial biopsies and bronchoalveolar lavage (BAL)
fluid cells of healthy controls and COPD patients. Using confocal microscopy and immunohistochemistry, the
protein expression of S100A7/psoriasin was investigated.
Results: Here, we report that S100A7/psoriasin, the major antimicrobial peptide of the human skin, is constitutively
expressed in perinuclear granules of human bronchial epithelial cells and alveolar macrophages. Whereas typical
activators of the innate immune response like TLR ligands and cytokines induced the upregulation of CXCL-8 mRNA
and release of CXCL-8 by epithelial cells, S100A7/psoriasin mRNA expression was not modulated. To investigate a
potential association of S100A7/psoriasin with COPD, S100A7/psoriasin mRNA expression was assessed in bronchial
biopsies and BAL fluid cells of patients at different stages of COPD and controls. Overall, 10 healthy individuals and 34
COPD patients were enrolled in this study. We found an association of S100A7/psoriasin mRNA expression with
bacterial detection in the tracheobronchial system (p = 0.0304), which was the strongest in individuals positive for with
S. aureus (p = 0.0005). However, S100A7/psoriasin mRNA expression was not altered during the progression of COPD.
Conclusions: S100A7/psoriasin gene expression is unchanged in the airways during COPD. The newly identified
association of S100A7/psoriasin with S. aureus may provide new insights into the antimicrobial defence response of
the human airways, leading to the induction of S100A7/psoriasin upon microbial challenge.
Background
The human lung serves as the largest interface between
the host and the environment, and its immune defenses
are critical for survival of the individual. A healthy adult
ventilates 16,000 - 24,000 times per day on average.
As the inhaled air is not sterile, respiratory cells are
frequently exposed to airborne microorganisms, includ-
ing pathogenic bacteria, viruses and fungi. Thus, an
effective innate immune system is required to protect
the airways and lungs from infection. Polymorphonuc-
lear granulocytes, alveolar macrophages and epithelial
cells play an important role in the innate immune
response of the lung [1]. Many of the receptors
employed by the innate immune system to identify
potential pathogens have been characterized [2,3]. The
effector molecules secreted by epithelial cells include
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antimicrobial substances [4,5]. Among these substances
are C-type lectins such as SP-A and SP-D [6], LL37/
CAP-18 [7], SLPI [8], and antimicrobial peptides such as
b-defensins [9-12].
The role of antimicrobial peptides (AMPs) in the
innate immune defense mechanisms of human airways
and lungs has recently gained more clinical interest [13].
Among a group of recently described antimicrobial pep-
tides that are produced by human epithelial cells,
S100A7/psoriasin exhibits very strong antimicrobial
activity at low molecular concentrations [14], which
was confirmed by comparing the activity of natural N-
acetylated S100A7/psoriasin with that of chemically
synthesized N-acetylated S100A7 [15].
S100A7/psoriasin belongs to the S100 family of EF-
hand calcium-binding proteins which consists of more
than 20 members with very distinct functions [16], ran-
ging from differentiation, cell cycle progression, intracel-
lular Ca
2+ signaling to leukocyte chemotaxis [17,18].
Chronic obstructive pulmonary disease (COPD) is one
of the leading causes of mortality and morbidity world-
wide [19]. The clinical hallmark of COPD is chronic
bronchitis and emphysema with progressive respiratory
tract inflammation and recurrent exacerbations at
advanced stages of the disease. Colonization of the
respiratory tract with various microorganisms is fre-
quently observed as COPD progresses and most exacer-
bations are attributed to bacteria or viruses [19].
However, little is known about specific components of
innate immunity that play a role in COPD progression.
We hypothesized that S100A7/psoriasin involved in the
airway mucosal immunity is differently regulated and
expressed in the lung during pathogenesis of COPD.
Furthermore, an association of S100A7/psoriasin gene
expression with positive microbial detection of the
respiratory tract was investigated.
Methods
Ethics statement
This study was approved by the Ethic Committee of the
Medical Faculty of the University of Lübeck. All study
participants provided written informed consent for the
collection of bronchial biopsies and BAL fluids.
Patients
Healthy volunteer controls and individuals with stages
1-4 COPD were recruited at the Medical Clinic of
the Research Center Borstel, Germany. We followed the
guidelines for grading disease severity in COPD of the
Deutsche Atemwegsliga and the Deutsche Gesellschaft
für Pneumologie (DGP), which is based on the interna-
tional GOLD classification and defined by an FEV1/VC
< 70% and FEV1 < 80% of the predicted value [20,21].
Following written informed consent bronchoscopy was
performed according to national guidelines [22] obtain-
ing bronchial biopsies from the middle lobe carina and
BAL fluid with 200-300 ml of normal saline.
BAL fluid and biopsy specimens were collected from
ten healthy subjects, two patients with mild COPD
(stage 1), 13 patients with moderate COPD (stage 2), 15
patients with severe COPD (stage 3) and four patients
with very severe COPD (stage 4). Healthy subjects for
bronchoscopy were volunteers with FEV1/VC > 70% of
the predicted value who were recruited by advertisement
on the basis that they did not have signs or symptoms
of COPD. Chronic illnesses (e.g. diabetes mellitus, renal
insufficiency, HIV-infection) were exclusion criteria for
study participant. Body plethysmography was performed
using Jaeger MasterScreen 601045. The 6-min walking
test (6MWD), arterial blood gas analysis, assessment of
the MRC dyspnoea scale and calculation of probability
of survival based on BODE score [23] completed the
clinical investigations. COPD exacerbations have been
defined according to Anthonisen criteria [24]. The basic
characteristics of the 34 COPD patients with stages 1-4
and 10 healthy controls are shown in Table 1.
For the staining of peripheral lung tissue we obtained
specimens of lung tissue from surgical specimens that
were resected from patients (n = 3) with the diagnosis
of bronchogenic carcinoma (informed consent obtained)
a n dr o u t i n e l yd i a g n o s e da tt h eD i v i s i o no fP n e u m o l o g y
at the Research Center Borstel. The specimens used
were tumor-free material at least 5 cm away from the
tumor front and were fixed then embedded in paraffin
using the HOPE (HEPES-glutamic acid buffer mediated
organic solvent protection effect) technique [25].
Detection of microbes in human material
Microbes were detected (BAL fluid, biopsy specimen)
following standard laboratory procedures. Human mate-
rial was inoculated on 5% sheep-blood agar, salt manni-
tol agar and Tarozzi bouillon for 48 h at 37°C.
Subcultures of Tarozzi bouillon followed after 24 h
incubation at 37°C to augment detection of bacteria.
Pure monocultures of E. coli and S. aureus were sub-
jected to biotyping using automated VITEK 2 biotyping
system, the API20E and the ID 32 Staph system (bio-
Mérieux, Marcy l’Etoile, France). S. aureus was addition-
ally identified by their ability to coagulate citrate plasma
and to cleave DNA and mannitol. Virochip microarrays
used in this study were identical to those previously
described [26]. RNA isolat e df r o mB A Lf l u i dw e r e
amplified and labeled using a modified Round A/B ran-
dom PCR method and hybridized to the Virochip
microarrays as reported previously [26,27].
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BAL fluid was centrifuged (at 500 × g for 10 min, 4°C)
and the sedimented cells washed twice with PBS (at
500 × g for 5 min, 4°C). Cell viability was assessed with
the use of the trypan-blue exclusion method and always
above 95%. Bronchial biopsy specimens (two pieces
from each study participant) were homogenized with
the use of the Pellet Pestle Cordless Motor (Kontes,
New Jersey, USA).
Cell culture
NCI-H727 (bronchial epithelial cell line) and A549 (lung
epithelial cell line) (bothf r o mA T C C ,M a n a s s a s ,V A )
were cultured at 37°C and 5% CO2 in RPMI1640 and
DMEM medium, respectively, supplemented with 10%
fetal calf serum and 1% of penicillin/streptomycin. For
treatments cells were cultured for the time indicated in
the presence of 100 ng/ml LPS (from Salmonella enter-
ica,s e r o v a rFriedenau, kindly provided by Prof. Dr. H.
Brade, Research Center Borstel, Gemany), 50 U/ml IL-
1b (Strathmann Biotech GmbH, Germany), or 5 ng/ml
recombinant human TNF-a (kindly provided by Prof.
D r .D .M ä n n e l ,R e g e n s b u r g ,G e r m a n y ) .F o rc o n t r o l s ,
only medium supplemented with 10% fetal calf serum
and 1% of penicillin/streptomycin was added to the
cells. S100A7/psoriasin and CXCL-8 mRNA expression
was determined as well as CXCL-8 production using an
ELISA (Biosource, Nivelles, Belgium) on cell culture
supernatants.
Real-time quantitative PCR
Total RNA was isolated from cells of BAL fluid, homo-
g e n i z e dl u n gb i o p s ys p e c i m e n sa n dc u l t u r e dl u n g
epithelial cells with the Absolutely RNA kit (Stratagene,
La Jolla, CA, USA). Reverse transcription was performed
in the presence of Superscript III Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA). Gene transcript levels
of S100A7/psoriasin, CXCL-8, b2 microglobulin (b2-M)
and porphobilinogen deaminase (PBG-D) were quanti-
fied by real-time PCR with the use of LightCycler 480
Probes Master, S100A7/psoriasin-specific primers and
the universal probe #60 (for S100A7/psoriasin) or Light-
Cycler 480 SYBR Green I Master (for CXCL-8, b2-M
and PBG-D) on a LightCycler 480 Instrument (Roche
Applied Science, Mannheim, Germany) according to the
manufacturer’s instructions. Standard curves were
obtained for each primer set with serial dilutions of
plasmid DNA containing the amplification product.
Absolute transcript levels are shown per one transcript
of b2-M or as a common logarithm of this ratio for
BAL fluid cells and bronchial biopsies. For cell lines
NCI-H727 and A549, variations in the amount in differ-
ent samples were corrected by PBG-D expression.
Sequences of the used primer sets were: S100A7/psoria-
sin: sense 5’-CTGCTGACGATGATGAAGGA-3’,a n t i -
sense 5’-CGAGGTAATTTGTGCCCTTT-3’;C X C L - 8 :
sense 5’-TTGCCAAGGAGTGCTAAAGAA-3’, antisense
5’-CAACCCTACAACAGACCCACAC-3’; b2-M: sense
5’-GCTGTGCTCGCGCTACTCTC-3’,a n t i s e n s e5 ’-GC
GGCATCTTCAAACCTCCAT-3’,P B G - D :s e n s e5 ’-AA
CCCTGCCAGAGAAGAGTG-3’,a n t i s e n s e5 ’-AGCC
GGGTGTTGAGGTTT-3’.
Cell staining
A549 cells were fixed with 2% paraformaldehyde in PBS
for 10 min. Cells were permeabilized with 0.25% Triton
X-100 in PBS for 5 min, incubated with the monoclonal
antibody to psoriasin/HID5/S100A7 (1:200, clone
Table 1 Baseline characteristics of the study participants providing BAL fluid and biopsy specimens
Characteristic Healthy controls COPD patients
Stage 1 Stage 2 Stage 3 Stage 4
Number 10 2 13 15 4
Age [years] 31.3 ± 7.8 (20-46) 73.5 ± 7.8 (68-79) 66.9 ± 9.9 (52-82) 66.4 ± 7.5 (46-77) 58.3 ± 3.6 (55-63)
Sex [M/F] 3/7 1/1 9/4 10/5 2/2
BMI 22.7 ± 1.9 (20.0-26.7) 27.2 ± 0.2 (27.0-27.3) 28.3-5.8 (22.5-44.6) 25.4 ± 4.7 (16.0-35.5) 21.3 ± 3.7 (16.2-24.5)
Pack years 2.9 ± 2.8 (1-7) 50.0 ± 14.1 (40-60) 41.9 ± 19.3 (10-85) 39.7 ± 16.6 (5-65) 42.5 ± 18.9 (30-70)
6MWD [m] 516.0 ± 49.3 (430-625) 305.0 ± 169.7 (185-425) 352.3 ± 127.1 (150-545) 291.0 ± 122.3 (0-465) 367.5 ± 88.6 (240-430)
FEV1 [%] 104.2 ± 16.6 (60.7-117.4) 89.9 ± 2.0 (88.5-91.3) 63.9 ± 10.2 (50.1-79.4) 38.2 ± 6.2 (30.2-47.3) 26.1 ± 2.8 (22.8-29.0)
VC [%] 108.5-26.4 (54.4-160.9) 107.3 ± 2.3 (105.7-108.9) 86.3 ± 12.4 (65.2-108.9) 69.2 ± 14.7 (42.6-97.7) 61.3 ± 10.6 (52.8-76.3)
FEV1/VC [%] 88.7 ± 8.6 (73.5-101.5) 73.1 ± 11.2 (65.2-81.0) 65.6 ± 12.6 (49.5-90.7) 46.8 ± 10.3 (30.0-66.3) 39.1 ± 7.5 (31.5-46.3)
BODE score † 2.0 ± 2.8 (0.0-4.0) 2.2 ± 2.3 (0.0-6.0) 5.1 ± 2.1 (2.0-9.0) 6.3 ± 1.0 (5.0-7.0)
Data are presented as mean ± SD (range), COPD: chronic obstructive pulmonary disease, M: male, F: female, BMI: body mass index, pack years: the number of
cigarettes smoked per day × number of years smoked)/20 (1 pack has 20 cigarettes), 6MWD: 6-minutes walking distance, FEV1: forced expiratory volume in one
second, VC: vital capacity, BODE score: index, which incorporates body mass index, airflow obstruction, dyspnoea and exercise capacity [22],% of predicted value,
† not determined. Stages 1 through 4 denote severity of disease according to the Deutsche Atemwegsliga and the Deutsche Gesellschaft für Pneumologie [20],
with higher number indicating greater severity.
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CA, USA) or mouse IgG1 (1:200, BD Biosciences, Hei-
delberg, Germany), washed and incubated with Alexa
Fluor 546 dye-conjugated goat-anti-mouse antibody
(1:300, Molecular Probes, Eugene, USA). Cells were
stained with TOTO-3-iodid (1:500, Invitrogen, Carlsbad,
CA, USA) and examined using a Leica confocal laser
scan microscope TCS SP1 (Bensheim, Germany). All
antibodies were diluted in PBS containing 10% BSA and
incubated for 30 min.
Immunohisto- and Immunocytochemistry
Sections of 4 μm of HOPE-fixed, paraffin-embedded
surgical lung specimens were cut, deparaffinized and
stained with the psoriasin/HID5/S100A7 antibody (1:500
in PBS). Signals were detected by sequential incubation
with biotinylated anti-mouse antibody and peroxidase-
conjugated streptavidin reagent (both 3-fold diluted in
PBS) by using 3-Amino9-Ethylcarbazole/H2O2 as chro-
mogen (DAKO, Denmark). Counterstain was performed
with Mayer’s hemalum before visualization of the immu-
noreactions. NCI-H727 cells were fixed with HOPE
technique [26] for 36 h and stained with the Psoriasin/
HID5/S100A7 antibody as described above. Negative
controls, where primary antibody was omitted, were
included.
Statistical analysis
All results are expressed as mean ± SD or mean ± SEM,
whereby each symbol represents a single sample. The
one-tailed hypothesis was tested using unpaired t-test
from log transformed data. Non-normal distributed
values were tested with Mann-Whitney test. Analysis of
variance of three or more unmatched groups was per-
formed with the use of the One-way ANOVA test fol-
lowed by Tukey’sM u l t i p l eC o m p a r i s o nt e s to r
nonparametric Kruskal-Wallis test. When the results
were significant, the unpaired t-test or Mann-Whitney
test, respectively, was performed for comparison
between the groups. Statistics were performed with
GraphPad Prism 5.02 software (GraphPad, San Diego,
CA, USA) where differences with p < 0.05 were consid-
ered significant.
Results
S100A7/psoriasin has been shown to be the primary anti-
microbial peptide of human skin for the killing of E. coli
[14]. However, the expression of S100A7/psoriasin in the
airways of human lungs has not been thoroughly investi-
gated before. Thus, we first tried to identify the expres-
sion of S100A7/psoriasin mRNA in the human bronchial
and lung epithelial cell lines NCI-H727 and A549,
respectively. Figure 1 represents S100A7/psoriasin
mRNA expression in both cell lines. Although S100A7/
psoriasin is constitutively expressed at low levels, its
expression can be further upregulated in keratinocytes
upon challenging with proinflammatory cytokines such
as IL-1 or TNF-a [14]. To further analyze whether lung
epithelial cells could also be stimulated for the induction
of an enhanced S100A7/psoriasin expression, we treated
the cells with the TLR4 ligand LPS, as well as with the
proinflammatory cytokines IL-1b and TNF-a but found
that S100A7/psoriasin mRNA expression remained
unchanged over at least 20 hours, regardless of the type
of stimuli used (Figure 2, right panels). On the other
hand, in NCI-H727 cells all three inflammatory stimuli
induced increased CXCL-8 mRNA and protein expres-
sion (Figure 2, upper left and middle panels), albeit with
a longer time course for the protein expression, while in
A549 cells LPS, unlike the cytokines, was ineffective with
respect to both mRNA and protein (Figure 2, lower left
and middle panels). Showing the same results, whole bac-
teria preparations from different Gram-negative and
Gram-positive bacteria have been used (data not shown).
Since the detection of S100A7/psoriasin mRNA in
bronchial and lung epithelial cells may not necessarily
reflect the protein expression of S100A7/psoriasin,
we used two different approaches to show S100A7/psor-
iasin protein expression in these cells. First, using
immunocytochemistry, we analyzed protein expression
Figure 1 Human bronchial and lung epithelial cells express
S100A7/psoriasin mRNA. RT-PCR was performed with specific
primers for S100A7/psoriasin and PBG-D as an internal control on
NCI-H727 and A549 cells. The expected size of PCR products is 248
bp for S100A7/psoriasin and 117 bp for PBG-D. PCR products were
separated on 1.5% agarose gel containing ethidium bromide. PCR
reaction in absence of cDNA was used as a negative control,
plasmid DNA as a positive control, 100-bp ladder as Marker.
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investigated if stimulation of the cells with the TLR4
ligand LPS would alter the S100A7/psoriasin expression.
T h ee x p r e s s i o no ft h en u c l e a rK i 6 7a n t i g e nw i t ht h e
MIB-1 antibody serves as a positive control (Figure 3C).
The results clearly show S100A7/psoriasin protein
expression in NCI-H727 cells, which appears to be loca-
lized in small perinuclear granules (Figure 3A and 3B).
However, as already seen with S100A7/psoriasin mRNA,
the expression level remained unchanged after stimula-
tion (Figure 3B). Secondly, to investigate S100A7/psoria-
sin protein expression in A549 cells, we used confocal
microscopy. As can be seen in Figure 4, S100A7/psoria-
sin is clearly expressed. Similar to the results obtained
with NCI-H727 cells, S100A7/psoriasin expression is
strongly concentrated in perinuclear granules (Figure
4A-C). In addition, a focal nuclear expression could also
be detected.
After the clear evidence that S100A7/psoriasin is
expressed in bronchial and lung epithelial cells we set
out to investigate if its expression could also be detected
in human lung tissue specimens (Figure 5). Indeed,
S100A7/psoriasin could be found in alveolar macro-
phages (Figure 5B and 5C) as well as in lung epithelial
Figure 2 S100A7/psoriasin mRNA levels remain unchanged after treatment with Toll-like receptor ligands or proinflammatory
cytokines. NCI-H727 (upper panel) and A549 cells (lower panel) were treated with 100 ng/ml LPS, 50 U/ml IL-1b, 5 ng/ml TNF-a, or medium
alone (Control) for the time indicated. CXCL-8 mRNA (left) and S100A7/psoriasin mRNA (right) were analyzed by quantitative real-time PCR, and
data are presented as mRNA level of both genes relative to PBG-D. CXCL-8 release (middle) was determined by ELISA. All values are depicted as
mean ± SEM of three independent experiments.
Figure 3 S100A7/psoriasin is expressed in small perinuclear
granules. S100A7/psoriasin immunocytochemical detection was
performed on (A) untreated and (B) LPS-treated (100 ng/ml, 21 hrs)
HOPE-fixed NCI-H727 cells using the monoclonal Psoriasin/HID5/
S100A7 (Imgenex, clone 47C1068) antibody. (C) Positive control is
shown by the expression of the nuclear Ki67 antigen with the MIB-1 (2
μg/ml) antibody. (D) Negative control was included omitting the
primary antibody. The results shown are representative of at least three
independent experiments. Magnification: 600× (A), 400× (B, C, D).
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istry in HOPE-fixed, paraffin embedded lung tissues.
Since S100A7/psoriasin is prominently involved in the
antibacterial immune response of the human skin, we
hypothesized that S100A7/psoriasin might also play a role
in inflammatory responses of the lung in patients with
COPD. Comparison of the expression levels of S100A7/
psoriasin mRNA in BAL fluid cells and biopsy samples
obtained from healthy individuals to that of patients with
stage 1-4 COPD by quantitative real-time PCR did not
reveal any significant differences (Figure 6). Variation of
S100A7/psoriasin mRNA expression was slightly higher in
the COPD group in both BAL fluid cells and biopsy sam-
ples. In addition, there was also neither a significant differ-
ence of S100A7/psoriasin mRNA expression with respect
to disease stages (s. Additional file 1a) nor did we detect
any correlation of S100A7/psoriasin mRNA expression
with FEV1,V Co rF E V 1/VC (s. Additional file 1b). How-
ever, the analysis of the correlation of S100A7/psoriasin
mRNA expression with cigarette smoking (i.e., pack years;
irrespective of health/COPD status) revealed a significant
correlation in biopsies (Spearman r = 0.3266, P value =
0.026) but not in BAL fluid cells (Spearman r = 0.2934,
P value = 0.0649, s. also Additional file 1c).
Figure 4 S100A7/psoriasin exhibits both, nuclear and
perinuclear localization. (A) Endogenous S100A/psoriasin was
visualized in A549 cells by confocal microscopy using the
monoclonal Psoriasin/HID5/S100A7 antibody (Imgenex, clone
47C1068). (B and E) Nuclei were visualized with Toto-3 iodide
(Molecular Probes). (D) Negative control was included by using
mouse immunoglobulin isotype control antibody (IgG1). (C and F)
Overlap between the S100A7/psoriasin staining or control IgG1
staining and nuclei staining, respectively, are shown in the merge
panels. Bars: 10 μm. The results shown are representative of at least
three independent experiments.
Figure 5 S100A7/psoriasin is expressed in lung epithelial cells and alveolar macrophages. S100A7/psoriasin immunohistochemical
detection was performed on HOPE-fixed, paraffin-embedded lung tissue specimens using the monoclonal Psoriasin/HID5/S100A7 antibody
(Imgenex, clone 47C1068). (A and D) negative controls without the primary antibody, (B and C) S100A7/psoriasin staining in alveolar
macrophages, (E and F) S100A7/psoriasin staining in lung epithelial cells. Magnification: 100× (A, B); 400× (C-F). Results shown are representative
of at least three independent experiments.
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microbes. When we compared the S100A7/psoriasin
mRNA expression in bronchial biopsies on the basis of
bacterial detection and regardless of their COPD status,
no differences could be seen (Figure 7A). However, in
BAL fluid cells a significant increased S100A7/psoriasin
mRNA level (p = 0.0304) could be found when bacteria
had been detected (Figure 7B). However, this mRNA
level in the bacteria positive group (positive) showed
very high variation, ranging from an expression level
seen in the pathogen negative group (negative) to up to
100 - 1000 fold higher expression. Since many different
bacterial species were detected (s. Additional file 2 for a
complete table), we could only form three groups for
statistical analysis: negative BAL fluid cells without any
bacteria detected and two groups, where we found
either E. coli or S. aureus. Whereas BAL fluid cells posi-
tive for E. coli displayed a similar S100A7/psoriasin
mRNA expression level as the control group, BAL fluid
cells positive for S. aureus exhibited a significantly
higher level of mRNA compared to the control group (p
= 0.0005) and the E. coli group (p = 0.0018) (Figure 7C).
Discussion
S100A7/psoriasin has been first identified and isolated
from lesional psoriatic skin [28] and has been shown to
act as a chemokine for T-cells and polymorphonuclear
granulocytes [29]. S100 proteins have been implicated in
innate immunity [30] and recently, S100A7/psoriasin has
been shown to be the most important factor produced by
Figure 6 S100A7/psoriasin mRNA expression remains unchanged during pathogenesis of COPD. BAL fluid cells (left) and bronchial
biopsies (right) were analyzed from COPD patients (N = 24 for BAL/N = 32 for biopsies) and healthy individuals (N = 8 in both). S100A7/
psoriasin mRNA expression was measured by quantitative real-time PCR. Expression levels were normalized to the expression of b2-M mRNA and
further log transformed. Results are depicted as mean ± SEM, each symbol representing a single probe.
Figure 7 S100A7/psoriasin mRNA expression is elevated upon pathogen exposure in BAL fluid cells. S100A7/psoriasin mRNA expression
level was compared on the basis of pathogen detection and independent of the COPD status. S100A7/psoriasin mRNA expression (A) in
bronchial biopsies without (negative, N = 19) or with detection of pathogens (positive, N = 20); (B) in BAL fluid cells without (negative, N = 8)
and with detection of pathogens (positive, N = 23); (C) in BAL fluid cells negative for a pathogen (N = 8) and positive for E. coli (N = 5) and S.
aureus (N = 5). Differences between the groups were analyzed by unpaired t-test from log transformed data with p < 0.05 considered as
significant.
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[14]. Among the plethora of antimicrobial peptides,
defensins and cathelicidins in particular have been shown
to be expressed in the human lung (for review see [13]).
However, the expression of S100A7/psoriasin in the
human lung has not been thoroughly investigated.
Recently, Bryborn et al. could show that S100A7/psor-
iasin is one of several proteins found to be down-
regulated in nasal lavage fluid of allergic patients [31] or
in infected tonsils as well as in tonsils from allergic indi-
viduals [32]. This connection with allergy has been
further substantiated with the association of a S100A7/
psoriasin gene polymorphism with allergic rhinitis [33].
S100A7/psoriasin has also been found in whole saliva of
patients with systemic sclerosis and lung involvement
[34]. However, a study by Zhang et al., investigating the
expression of S100A7/psoriasin in certain lung cancers,
did not find any substantial protein expression in nor-
mal lung tissue [35] and the recent finding that S100A7/
psoriasin is highly expressed in the tongue may have
also been the reason for its detection in whole saliva
[36]. In the present study, we clearly demonstrate that
S100A7/psoriasin is expressed in human bronchial and
lung epithelial cells and cell lines as well as in alveolar
macrophages of healthy individuals and patients with
COPD at different stages of the disease.
The expression of S100A7/psoriasin was upregulated
upon stimulation of human keratinocytes with certain
bacteria [37]. Recently, the ligand driving this upregula-
tion has been identified as bacterial Flagellin [38]. After
identifying the expression of S100A7/psoriasin mRNA
and protein in the human lung epithelial cell lines we
sought to determine if the level of expression depends
on the activation status of the cells. We used typical
activators of innate immune responses such as cytokines
(TNF-a or IL-1b) and whole bacteria (data not shown).
However, in contrast to keratinocytes, the S100A7/psoria-
sin mRNA level did not change upon stimulation. The
intracellular localization as well as the molecular mechan-
ism of S100A7/psoriasin secretion has not been investi-
gated so far. In both, bronchial and alveolar epithelial cells,
S100A7/psoriasin protein was granular and expressed in
confined perinuclear compartments. Interestingly, the
amount of S100A7/psoriasin expressed appears to be
rather high, indicating a potential prominent role of
S100A7/psoriasin in the innate response of the bronchial
and lung epithelium. This is further substantiated by the
immunohistochemical protein staining of S100A7/psoria-
sin in human lung tissues, since it is particularly expressed
in ciliated epithelial cells. In addition, we also show
S100A7/psoriasin expression in alveolar macrophages.
In the present study we do not find any significant dif-
ferences in the expression level of S100A7/psoriasin
mRNA, when comparing COPD patients to healthy
individuals, where disease in the COPD patients ranged
from mild to very severe. This could indicate that
S100A7/psoriasin plays only a minor role in chronic
pulmonary inflammation in COPD. However, dividing
all samples in groups depending on the status of patho-
gen detection (bacteria, fungi and/or virus), we identified
a significant increase of S100A7/psoriasin mRNA in the
group where microorganisms were detected in the lower
respiratory tract. Although many different pathogens
could be identified, most of the pathogens were only
found once or twice, precluding any statistical analysis.
Two bacterial strains, E. coli and S. aureus, have been
detected in five samples each. In contrast to previous
observations on the specific antimicrobial effectivity of
S100A7/psoriasin in the skin [14], we found that sam-
ples of patients where S. aureus had been detected dis-
played a significant higher level of S100A/psoriasin
mRNA than patients where E. coli has been detected.
Moreover, S100A7/psoriasin mRNA levels were not ele-
vated in patients positive for E. coli in their respiratory
tract compared to those where no pathogens were
detected. As the bactericidal efficiency of S100A7/psor-
iasin against S. aureus is much lower than against E. coli
[14], these results could indicate that the regular consti-
tutive levels of S100A7/psoriasin expression are suffi-
cient to contain a potential E. coli infection but are
inadequate to combat S. aureus.
Conclusions
In summary, we found that S100A7/psoriasin is constitu-
tively expressed in the lower human airways. Depending
on bacterial occurrence in general and S. aureus in parti-
cular, S100A7/psoriasin is found to be upregulated and
thus enhances the epithelial barrier function of the lower
respiratory tract upon microbial challenge.
Additional material
Additional file 1: S100A7/psoriasin mRNA expression in different
COPD stages and correlation with lung function parameters and
cigarette smoking. a) S100A7/psoriasin mRNA expression in healthy
controls and COPD I-II/COPD III-IV disease stages. b) Correlation analysis
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Correlation analysis of S100A7/psoriasin mRNA expression with cigarette
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